Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights Initial clinical response data for AlloNK ® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial design for AlloNK expected in first half of 2026 Strengthened board and executive leadership with

#ARTV Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/ARTV/artiva-biother...

Trade Alerts, Wednesday January 14, 2026 – Crystal Equity Research

Small-cap stocks with declining money flow, Wed Jan 14th - #COSM #BLZR #RVP #ZJYL #SHEN #PAYS #MCRI #GABC #FACT #CENTA #BEEM #ARTV #MEG #BOC #ADCT - More: crystalequityresearch.com/trade-alerts... - #smallcap

👀 #ARTV

#ARTV on short squeeze, strong clinical validation and potential 600% upside over 12 months. #StocksToWatch #StocksToBuy #Biotech

Most Searched, Monday December 15, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Dec 15th - #QUBT #KYTX #NVTS #JBLU #CLYM #RR #BEAT #BTBT #RADX #DNN #ARTV #BITF #MIST #PLUG #BBAI #USAR #TLRY #ONDS #IRBT #CLSK - More: crystalequityresearch.com/most-searche... - #smallcap

Trade Alerts, Monday December 15, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Mon Dec 15th - #UAG #RADX #MASK #QIPT #KYTX #KVHI #IMNM #ARTV - More: crystalequityresearch.com/trade-alerts... - #smallcap

A observar as votações das medidas dos vários partidos para o #OE26 na #ARTV e reparar no tom apressado e quase de leilão das mesmas.

#QuaseFimDeSemana

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease 32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were treated in community rheumatology trial sites with no specialized oncology oversight, demonstrating

#ARTV Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

www.stocktitan.net/news/ARTV/artiva-biother...

#ARTV Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/ARTV/artiva-biother...

News; ( NASDAQ: #ARTV ) Biotech Stock Artiva Biotherapeutics (Nasdaq: ARTV) Soars on News FDA has granted Fast Track Designation to AlloNK

News; ( NASDAQ: #ARTV ) Artivas AlloNK Secures FDA Fast Track Designation for Refractory Rheumatoid Arthritis; Stock Climbs

📢 Stocks Trending NOW: #AXP #RANI #ZION #LLY #WAL #ARTV #TFC #GTLB #NVO #SLB

Trade Alerts, Thursday October 16, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Thu Oct 16th - #WBUY #TOYO #YDKG #UROY #SATL #OCCI #LOOP #KZR #HYPR #GBIO #FOSL #CCII #ARTV #IIIN - More: crystalequityresearch.com/trade-alerts... - #smallcap

Artiva (ARTV) Q2 Loss Widens 19.7% | The Motley Fool

#ARTV #1065a760-500f-4586-bc7a-ca980c8efb93 #data-news

Origin | Interest | Match

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights Artiva Biotherapeutics (NASDAQ: ARTV) reported its Q1 2025 financial results and business updates. The company announced IND clearance and initiation of a global basket trial exploring AlloNK® + rituximab in multiple autoimmune conditions, marking the first allogeneic cell therapy trial for rheumatoid arthritis and Sjögren's disease in the U.S. The company ended Q1 2025 with $166.0 million in cash, extending runway into Q2 2027.Key financial metrics include R&D expenses of $17.1 million (up from $11.2M in Q1 2024), G&A expenses of $5.1 million (up from $3.6M), and a net loss of $20.3 million (increased from $14.0M). The company's B-NHL trial data showed promising results comparable to approved auto-CAR-T therapies. Initial safety and translational data are expected by year-end 2025, with clinical response data in the lead indication planned for 1H2026. [ "Strong cash position of $166.0M providing runway into Q2 2027", "First-mover advantage in allogeneic cell therapy for RA and Sjögren's disease in U.S.", "B-NHL trial data showing complete response rates comparable to approved auto-CAR-T therapies", "Expansion of development team with autoimmune expertise", "No hospitalization requirement for AlloNK dosing, supporting community-based treatment" ]

#ARTV Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

www.stocktitan.net/news/ARTV/artiva-biother...

#digitalart #artv #illustrationart #illustration

Artiva Secures 2-Year Cash Runway Despite $65M Loss: Key Pipeline Updates Fresh from $179M IPO, Artiva maintains strong financial position with upcoming AlloNK clinical readouts. See pipeline progress and financial outlook analysis.

#ARTV Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

www.stocktitan.net/news/ARTV/artiva-biother...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Wed Mar 12th - #RGLS #SAGE #VIOT #ARMN #DOUG #PFC #OPRX #LENZ #ARTV #IPI #HG #FOA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

This Saturday I'll be vending my wares at Nerd Force Fan Fest with my friend camo_and_comics (on insta)!

Our tables are right next to one another, so drop by both our tables!

#nerdforce #nerdforcefanfest2025 #nerdforcefanfest #artv #artwork #merch #merchandise #sell #selling #vendor #comiccon

Human anatomy is smth else😶‍🌫️

#fyp #drawing #artv

Tryptic piece. A very nice commission experience.

#artonbluesky #artv #fun #fineart #abstact #abstractart

Character in a prone position, tails fluffed and eyes whited out

Feral Kaori doodle

#artv #artist #oc

:D
#арт
#artv

#zombie #Artv

Desenho meio Ruim :P